Papillary Renal Cell Carcinoma Type 1 vs Type 2: Histology Compared
Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that accounts for about 10-15% of all renal cell carcinomas. It is characterized by fingerlike projections called papillae. Histologically, PRCC is further classified into two main types: type 1 and type 2, each with distinct morphological features and clinical implications.
The distinction between these types is crucial as they differ in terms of histological appearance, genetic alterations, biological behavior, and prognosis. Here, we delve into the unique aspects of PRCC type 1 and type 2, providing a comprehensive comparison to help clinicians and pathologists better understand and manage these conditions.
PRCC Type 1 Histology
PRCC type 1 is characterized by tubular architecture and hence is also known as tubular papillary renal cell carcinoma. The papillae in type 1 PRCC are thin and delicate with a complex, arborizing pattern. The cortex-to-medulla ratio is usually high.
Under the microscope, type 1 PRCC shows a typical pattern of back-to-back, cystic, and hemorrhagic tubules. The tumor cells in type 1 PRCC exhibit a low nuclear grade with scant cytoplasm and inconspicuous nucleoli. They also frequently show immunoreactivity for the t(7;11)(p15;q12) translocation, leading to the fusion of TFE3 and MGA genes.
Histological Variations
Diverse histological variants can be seen in type 1 PRCC, including the eosinophilic, chromophobic, and collecting duct-like types. The eosinophilic variant exhibits abundant eosinophilic cytoplasm, while the chromophobic variant has pale or empty cytoplasm. The collecting duct-like variant mimics the appearance of the normal collecting ducts, with small, cuboidal cells.
Type 1 PRCC can also show indistinct borders with the normal kidney tissue and infiltrate into the perinephric fat, renal vein, or inferior vena cava. Vascular or lymphatic invasions should be assessed carefully as they impact staging and prognosis.
Molecular Genetics
The most common genetic alteration in type 1 PRCC is the translocation of the TFE3 gene. Other than the t(7;11) translocation, variant translocations involving TFE3, such as t(X;1)(p11;q21), t(6;11)(p21;q12), and t(6;11)(q15;p15), can also be found.
The identification of TFE3 rearrangement has significant implications for targeted treatments. For instance, the FDA has recently approved the use of the tyrosine kinase inhibitor ponatinib for TFE3 fusion-positive alveolar soft part sarcoma, which is based on similar molecular pathways involved in type 1 PRCC.
PRCC Type 2 Histology
Contrasting with type 1, PRCC type 2 is characterized by the presence of eosinophilic cytoplasm and low mitotic activity. The papillae in type 2 PRCC are typically broad and club-shaped, and the cortex-to-medulla ratio is usually low.
Microscopically, type 2 PRCC exhibits a distinctly papillary architecture with hobnail or plasmacytic cells lining the papillae. The abundance of eosinophilic cytoplasm gives the tumor cells a distinctive appearance, hence the name eosinophilic papillary renal cell carcinoma. The tumor cells also often demonstrate immunoreactivity for vimentin and AMACR.
Histological Associations
Type 2 PRCC is often associated with regional lymph node involvement and venous invasion, although it tends to have a more indolent clinical course compared to other subtypes of RCC. It also shows a higher stage and grade at presentation, and thus, its prognosis is less favorable than type 1 PRCC.
Morphologically, type 2 PRCC can show some features of other RCC subtypes, such as low-grade Tata next clear cell RCC ( गिर sovint-developed). This overlap in morphology may pose a diagnostic challenge and suggests the importance of careful consideration of other clinical and histological parameters.
Molecular Genetics
Unlike type 1 PRCC, type 2 PRCC does not typically harbor TFE3 rearrangements. Instead, it is associated with trisomy or tetrasomy of chromosomes 7 and 17. This chromosomal imbalance leads to increased expression of oncogenes like MET and YAP1, contributing to tumorigenesis.
Research into the molecular landscape of type 2 PRCC is still underway. Recent studies have identified potential therapeutic targets, including the MET and ETV6/NTRK3 fusion, which may pave the way for more personalized treatment strategies in the future.
The understanding of papillary renal cell carcinoma, particularly the distinction between type 1 and type 2 histology, is an ongoing endeavor in modern pathology. As new targeted therapies emerge, accurate classification of these entities becomes increasingly important. Pathologists must always strive to refine their diagnostic skills, including the use of molecular tools, to ensure the best possible patient care.